Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors

Antimicrob Agents Chemother. 2008 May;52(5):1862-4. doi: 10.1128/AAC.01208-07. Epub 2008 Mar 10.

Abstract

Rapid emergence of resistance to monotherapy with virus-specific inhibitors necessitates combination therapy. ACH-806 is a hepatitis C virus NS4A inhibitor with a novel mechanism of action and resistance pathway. This compound was synergistic with NS3 protease inhibitors and NS5B nucleoside and nonnucleoside polymerase inhibitors.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology*
  • Cell Line, Tumor
  • Drug Resistance, Viral
  • Drug Synergism
  • Hepacivirus / drug effects*
  • Humans
  • Molecular Structure
  • Phenylthiourea / analogs & derivatives
  • Phenylthiourea / chemistry
  • Phenylthiourea / pharmacology
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / pharmacology*
  • RNA-Dependent RNA Polymerase / antagonists & inhibitors*
  • Viral Nonstructural Proteins / antagonists & inhibitors*

Substances

  • 1-(4-pentyloxy-3-trifluoromethylphenyl)-3-(pyridine-3-carbonyl)thiourea
  • Antiviral Agents
  • NS4A protein, flavivirus
  • Protease Inhibitors
  • Viral Nonstructural Proteins
  • Phenylthiourea
  • RNA-Dependent RNA Polymerase